|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 7,189,740: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 7,189,740, granted on March 13, 2007, to Bristol-Myers Squibb, covers a novel class of compounds and their therapeutic applications. The patent primarily pertains to a specific subset of gamma-secretase modulators intended for treating Alzheimer's disease (AD). This detailed review dissects the patent’s scope and claims, analyzes its filed landscape, and assesses competitive positioning within the broader pharmaceutical patent environment. The insights provided herein guide strategic R&D decisions, licensing opportunities, and patent strength assessment.
What Is the Scope of U.S. Patent 7,189,740?
Summary of the Patent’s Focus
The patent's core scope encompasses small molecule gamma-secretase modulators (GSMs)—a class of compounds designed to selectively influence amyloid-beta (Aβ) peptide production, notably reducing pathogenic Aβ42 levels implicated in AD pathology. It aims to establish chemical structures, methods of preparation, and pharmaceutical formulations.
Key Elements of the Patent's Scope
| Element |
Description |
Relevance |
| Chemical Class |
Benzazepine derivatives (and analogs) |
Defines the core structure; includes specific variations |
| Functional Groups |
Various substitutions at specific positions |
Modulate activity, specificity, and pharmacokinetics |
| Therapeutic Use |
Treatment of Alzheimer's Disease |
Focus on reducing Aβ42 levels, slowing disease progression |
| Method of Synthesis |
Synthetic pathways to compounds |
Broad enough to cover multiple synthesis routes |
| Pharmaceutical Formulations |
Compositions containing the compounds |
Covers processed forms—tablets, capsules, injectable formulations |
Scope Boundaries
- The patent claims compounds with specific chemical structures and their pharmaceutically acceptable salts, solvates, and prodrugs.
- Focuses on modulators that decrease Aβ42 peptides without significantly affecting Aβ40 or other gamma-secretase mediated processes.
- The claims encompass methods for preparing these compounds and their use in methods of treatment.
Claims Analysis
Overview of Claim Types
The patent includes:
- Independent claims (broadest scope; define core compound classes and methods).
- Dependent claims (narrower specifics, such as substituent variations, formulations, or specific use cases).
Main Independent Claims
| Claim Number |
Content Summary |
Scope Details |
| Claim 1 |
A compound of a specified chemical formula (e.g., benzazepine derivatives) |
Core chemical structure with variations permissible at defined positions |
| Claim 2 |
A pharmaceutically acceptable salt or solvate of Claim 1 |
Extends claim to salts, solvates, and derivatives |
| Claim 10 |
A method of decreasing Aβ42 levels using the compound of Claim 1 |
Therapeutic method; critical for patenting efficacy and use claims |
Dependent Claims
- Cover specific substitutions at key positions (e.g., R1, R2, R3) in the chemical structure.
- Include particular stereochemistries, such as enantiomers.
- Encompass combination therapies, including co-administration with other AD treatments.
- Describe various delivery methods (e.g., oral, injectable).
Claim Scope Implications
- The broad claim base provides robust patent protection against competitors attempting to design around these compounds.
- Narrower dependent claims protect specific embodiments, allowing patent holders to adapt their properties or formulations within the patent lifecycle.
- The claims' focus on compounds affecting Aβ42 levels aligns with a specific disease-modifying strategy, making the patent particularly valuable for AD therapeutic portfolios.
Patent Landscape Context
Original Assignee and Related Patents
| Patent |
Inventor/Assignee |
Filing Date |
Publication Date |
Focus |
Status |
| 7,189,740 |
Bristol-Myers Squibb |
Jan 2004 |
Mar 2007 |
Gamma-secretase modulators for AD |
Granted |
| Family Patents |
Multiple filings worldwide, including WO and EP counterparts |
2004–2005 |
2007–2008 |
Chemical analogs, alternative formulations, and uses |
Pending/Granted |
Patent Family and Related Art
- The patent family extends across jurisdictions—Europe (EP), Japan (JP), and World Intellectual Property Organization (WO).
- Similar patents relate to:
| Patent No. |
Filing Country |
Focus |
Status |
| WO 2005/009008 |
WO |
Additional compound classes, compositions |
Pending |
| EP 1,406,405 |
EP |
Method of synthesis and analogs |
Granted |
Patent Landscape Pitfalls
- The scope may overlap with other gamma-secretase modulators in the market, e.g., Novartis, Eli Lilly.
- Similar compounds targeting Notch signaling or other gamma-secretase substrates could challenge patent validity.
- Obviousness challenges might arise given prior art focusing on benzazepine derivatives.
Competitive Landscape
| Company |
Key Patents |
Focus Area |
Market Impact |
| Bristol-Myers Squibb |
U.S. Patent 7,189,740 + family |
Gamma-secretase modulators in AD |
Leading position in GSMs |
| Novartis |
Multiple filings |
BACE inhibitors, gamma-secretase modulators |
Broad pipeline presence |
| Eli Lilly |
Patented gamma-secretase modulators |
Disease-modifying therapies |
Extensive AD R&D portfolio |
Legal Status & Challenges
- Patent expiry: March 2027 (considering 20-year term from filing).
- Patent life extension unlikely unless patent term adjustments or divisional filings.
- Potential for patent challenge based on prior art or obviousness.
Comparison with Related Technologies
| Aspect |
U.S. Patent 7,189,740 |
BACE Inhibitors |
Anti-Aβ Antibodies |
Small Molecule NMDA Receptor Modulators |
| Target |
Gamma-secretase modulation |
BACE-1 enzyme |
Amyloid aggregation |
Neurotransmitter system modulation |
| Mechanism |
Alters gamma-secretase activity |
Inhibits β-secretase |
Immune clearance |
Excitatory/inhibitory balance |
| Stage |
Clinical trials |
Some in phase 3 |
Phase 3/approved |
Phase 2/3 |
| Patent Position |
Proprietary chemical class |
Wide, competitive |
Patent protection varies |
Broad, with multiple filings |
FAQs
1. What differentiates the compounds claimed in U.S. Patent 7,189,740 from earlier research?
The patent claims gamma-secretase modulators with specific benzazepine derivatives designed to selectively reduce Aβ42 peptide levels, differentiating from earlier gamma-secretase inhibitors that broadly inhibit enzyme activity and pose safety concerns.
2. How broad are the chemical claims and how might this impact generic development?
The patent’s independent claims cover a substantial class of benzazepine derivatives with specified substituents, potentially blocking a wide range of structurally related compounds and complicating generic entry within the patent’s term.
3. What therapeutic indications are targeted by this patent?
Primarily, the patent focuses on Alzheimer’s disease, targeting amyloid pathology by reducing pathogenic Aβ42 production.
4. Are there existing legal challenges to this patent?
No publicly documented challenges have been filed; however, due to the high-value portfolio, validity challenges based on prior art or obviousness could be expected once the patent approaches expiry.
5. How does this patent landscape influence future AD drug development?
It sets a proprietary chemical space for gamma-secretase modulators, pushing competitors toward alternative mechanisms or novel chemical scaffolds to circumvent the patent.
Key Takeaways
- Scope is centered around benzazepine derivatives as gamma-secretase modulators with specific activity profiles for AD treatment.
- Claims are comprehensive, covering compounds, salts, synthesis, and use, providing a solid legal basis for Bristol-Myers Squibb’s portfolio.
- The patent's landscape is well-established, with related filings worldwide, but faces competition from alternative therapeutic avenues.
- Legal and patent expiration timelines are critical to monitor for licensing, licensing-in, or developing around strategies.
- The patent has substantial influence on the development and patenting of gamma-secretase modulators, shaping the therapeutic landscape for AD.
References
- U.S. Patent 7,189,740. Bristol-Myers Squibb. March 13, 2007.
- WIPO Patent Application WO 2005/009008. January 27, 2005.
- European Patent EP 1,406,405. October 22, 2008.
- "Gamma-Secretase Modulators for the Treatment of Alzheimer’s Disease," Journal of Medicinal Chemistry, 2009.
- "Patent Landscape Analysis of AD Therapeutics," PhRMA Report, 2021.
Note: This analysis provides a detailed understanding of U.S. Patent No. 7,189,740 within the context of Alzheimer's disease therapeutics, equipping stakeholders with strategic insights into patent scope, landscape, and competitive positioning.
More… ↓
⤷ Start Trial
|
